Missing content? – Request curation!
Request curation for specific Genes, Variants, or PubMed publications.
Have questions, comments, or suggestions? - Let us know!
Email us at : ckbsupport@genomenon.com
| Therapy Name | JNJ-64457107 |
| Synonyms | |
| Therapy Description |
JNJ-64457107 (mitazalimab) is a CD40 agonist that may lead to a T-cell dependent antitumor response, potentially resulting in tumor growth inhibition (PMID: 25316820, PMID: 30664811). |
| Drug Name | Trade Name | Synonyms | Drug Classes | Drug Description |
|---|---|---|---|---|
| JNJ-64457107 | ADC-1013|Mitazalimab|JNJ 7107 | CD40 Antibody 16 | JNJ-64457107 (mitazalimab) is a CD40 agonist that may lead to a T-cell dependent antitumor response, potentially resulting in tumor growth inhibition (PMID: 25316820, PMID: 30664811). |
| Molecular Profile | Indication/Tumor Type | Response Type | Therapy Name | Approval Status | Evidence Type | Efficacy Evidence | References |
|---|
| Clinical Trial | Phase | Therapies | Title | Recruitment Status | Covered Countries | Other Countries |
|---|---|---|---|---|---|---|
| NCT02829099 | Phase I | JNJ-64457107 | A Study of Safety, Pharmacokinetics and Pharmacodynamics of JNJ-64457107 in Participants With Advanced Stage Tumors | Completed | ISR | ESP | 0 |
| NCT06205849 | Phase I | JNJ-64457107 | Intra-tumoral Mitazalimab (CD40 Antibody) With Irreversible Electroporation (IRE) in Locally Advanced Pancreas Cancer | Recruiting | USA | 0 |